Search results
Results from the WOW.Com Content Network
Capromorelin, sold under the brand names Entyce and Elura, is a medication used for the management of weight loss in cats and dogs. [5] [6] Capromorelin is a ghrelin receptor agonist known to increase appetite and weight gain. [2] Capromorelin was developed by Pfizer. [7] [8] Capromorelin was approved for veterinary use in the United States in ...
bedinvetmab - nerve growth factor inhibitor monoclonal antibody used for osteoarthritis in dogs; benazepril – ACE-inhibitor used in heart failure, hypertension, chronic kidney failure and protein-losing nephropathy; bethanechol – stimulates bladder contractions, tranquilizer, makes the patient feel no pain; bexagliflozin - oral antidiabetic ...
Growth hormone secreting pituitary tumours in dogs have only been observed in male dogs of large breeds. Excessive growth hormone secretion caused by progestone use has been seen in a variety of breeds of varying size, as well as in mixed breed dogs , the same is true of growth hormone excess brought on by the oestrous cycle.
Gonadotropin-releasing hormone antagonists (GnRH antagonists) are a class of medications that antagonize the gonadotropin-releasing hormone receptor (GnRH receptor) and thus the action of gonadotropin-releasing hormone (GnRH).
Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. [1] [2] [3] It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. [4]
This gene encodes a protein that is a transmembrane receptor for growth hormone. [10] [11] Binding of growth hormone to the receptor leads to reorientation of a pre-assembled receptor dimer dimerization (the receptor may however also exist as monomers on the cell surface [12]) and the activation of an intra- and intercellular signal transduction pathway leading to growth. [13]
Moxonidine is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. [5] [6] It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure.
Pralmorelin (brand name GHRP Kaken 100; former developmental code names KP-102, GPA-748, WAY-GPA-748), also known as pralmorelin hydrochloride and pralmorelin dihydrochloride (), as well as, notably, growth hormone-releasing peptide 2 (GHRP-2), is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by Kaken Pharmaceutical in Japan in a single-dose formulation for ...